Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00424632
First received: January 18, 2007
Last updated: June 14, 2012
Last verified: June 2012
Results First Received: March 21, 2012  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Solid Tumors
Intervention: Drug: PF-03814735

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
59 participants enrolled and 57 sequentially assigned to treatment in Schedule A or B of study treatment. Schedule A: starting dose was 5 milligrams per day (mg/day) and dose was escalated up to 100 mg/day. Schedule B: starting dose determined based on occurrence of dose limiting toxicities and maximum tolerated dose in Schedule A.

Reporting Groups
  Description
PF-03814735 5 mg (Schedule A) Participants received daily dosing of PF-03814735 of 5 milligrams (mg) administered orally (PO) every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 10 mg (Schedule A) Participants received daily dosing of PF-03814735 of 10 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 20 mg (Schedule A) Participants received daily dosing of PF-03814735 of 20 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 40 mg (Schedule A) Participants received daily dosing of PF-03814735 of 40 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 60 mg (Schedule A) Participants received daily dosing of PF-03814735 of 60 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 80 mg (Schedule A) Participants received daily dosing of PF-03814735 of 80 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 100 mg (Schedule A) Participants received daily dosing of PF-03814735 of 100 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 40 mg (Schedule B) Participants received daily dosing of PF-03814735 of 40 mg administered PO every morning on an empty stomach for 10 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 50 mg (Schedule B) Participants received daily dosing of PF-03814735 of 50 mg administered PO every morning on an empty stomach for 10 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 60 mg (Schedule B) Participants received daily dosing of PF-03814735 of 60 mg administered PO every morning on an empty stomach for 10 consecutive days out of 21-day cycles on an outpatient basis.

Participant Flow:   Overall Study
    PF-03814735 5 mg (Schedule A)     PF-03814735 10 mg (Schedule A)     PF-03814735 20 mg (Schedule A)     PF-03814735 40 mg (Schedule A)     PF-03814735 60 mg (Schedule A)     PF-03814735 80 mg (Schedule A)     PF-03814735 100 mg (Schedule A)     PF-03814735 40 mg (Schedule B)     PF-03814735 50 mg (Schedule B)     PF-03814735 60 mg (Schedule B)  
STARTED     1     1     1     4     3     15     7     3     16     6  
COMPLETED     0     0     0     0     0     0     0     0     0     0  
NOT COMPLETED     1     1     1     4     3     15     7     3     16     6  
Death                 0                 0                 0                 0                 0                 2                 0                 0                 0                 0  
Adverse Event                 0                 0                 0                 0                 0                 0                 0                 0                 3                 2  
Global deterioration of health status                 0                 0                 0                 1                 1                 0                 0                 0                 0                 0  
Objective progression or relapse                 1                 1                 1                 2                 2                 13                 7                 3                 12                 4  
Unspecified                 0                 0                 0                 1                 0                 0                 0                 0                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
PF-03814735 (Schedule A) Participants received daily dosing of PF-03814735 of 5, 10, 20, 40, 60, 80, or 100 mg administered PO every morning on an empty stomach for 5 consecutive days out of 21-day cycles on an outpatient basis.
PF-03814735 (Schedule B) Participants received daily dosing of PF-03814735 of 40, 50, or 60 mg administered PO every morning on an empty stomach for 10 consecutive days out of 21-day cycles on an outpatient basis.
Total Total of all reporting groups

Baseline Measures
    PF-03814735 (Schedule A)     PF-03814735 (Schedule B)     Total  
Number of Participants  
[units: participants]
  32     25     57  
Age  
[units: years]
Mean ± Standard Deviation
  63.6  ± 9.0     58.2  ± 10.2     61.2  ± 9.8  
Gender  
[units: participants]
     
Female     18     13     31  
Male     14     12     26  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) Graded According to Common Terminology Criteria Adverse Events (CTCAE), Version 3   [ Time Frame: Day 1 up to Day 21 of first cycle ]

2.  Secondary:   Maximum Observed Serum Concentration (Cmax)   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

3.  Secondary:   Time for Maximum Observed Serum Concentration (Tmax)   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

4.  Secondary:   Area Under the Serum Concentration Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

5.  Secondary:   Area Under the Serum Concentration Time Profile From Time 0 to Time Tau (τ), the Dosing Interval, Where τ = 24 Hours (AUCτ).   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

6.  Secondary:   Minimum Observed Serum Trough Concentration (Cmin)   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

7.  Secondary:   Observed Serum Accumulation Ratio (Rac)   [ Time Frame: Schedule B Day-5: pre-dose, 0.5, 1, 2, 4, 6, 10, 24, 32, 48, and 72 hours post-dose, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

8.  Secondary:   Terminal Half-life (t 1/2)   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

9.  Secondary:   Urine Pharmacokinetics   [ Time Frame: Schedule A Cycle 1/Day 4, Schedule B Cycle 1/Day 9: pre-dose, 0.5, 1, 2, 4, 6, 10, and 24 hours post-dose ]

10.  Secondary:   Summary of Tumor Metabolism Assessed by Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET)   [ Time Frame: Baseline (Schedule A or Schedule B Day -7) and Schedule A Cycle 1/Day 3 or Day 4, Schedule B Cycle 1/Day 8 or 9 ]

11.  Secondary:   Target Modulation by Phosphohistone H3 (pH3) Expression in Tumor Tissue (IHC)   [ Time Frame: Schedule A Cycle 1 or Cycle 2 /Day 4 or Day 5, Schedule B Cycle 1/Day 9 or Day 10 ]

12.  Secondary:   Number of Participants With Objective Tumor Response   [ Time Frame: Every 2 cycles (each cycle=21 days) until disease progression or participant discontinuation; maximum follow-up was from baseline up to 12 cycles ]

13.  Secondary:   Time to Progression   [ Time Frame: Baseline, every 2 cycles (each cycle=21 days) until disease progression or participant discontinuation; maximum follow-up was from baseline up to 12 cycles ]

14.  Secondary:   Duration of Response   [ Time Frame: Every 2 cycles (each cycle=21 days) until disease progression or participant discontinuation; maximum follow-up was from baseline up to 12 cycles ]

15.  Secondary:   Germ Line Polymorphism of Candidate Genes Targeted by PF-03814735   [ Time Frame: Schedule A Cycle 1 or Cycle 2 /Day 4 or Day 5, Schedule B Cycle 1/Day 9 or Day 10 (each cycle=21 days) ]

16.  Secondary:   Aurora Gene Somatic Mutations/Amplification and Pathway Genes in Tumor Tissue   [ Time Frame: Schedule A Cycle 1 or Cycle 2 /Day 4 or Day 5, Schedule B Cycle 1/Day 9 or Day 10 (each cycle=21 days) ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.govCallCenter@pfizer.com


No publications provided by Pfizer

Publications automatically indexed to this study:

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00424632     History of Changes
Other Study ID Numbers: A9491001
Study First Received: January 18, 2007
Results First Received: March 21, 2012
Last Updated: June 14, 2012
Health Authority: United States: Food and Drug Administration